No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection By Ogkologos - June 22, 2026 9 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin MOST POPULAR ΚΑΡΚΙΝΟΣ ΧΟΛΗΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 Classmates Surprise Badly Bullied Teen After Weeks Of Planning: ‘You Deserve... March 29, 2019 Adding Pembrolizumab to Standard Chemotherapy, Followed by Pembrolizumab Maintenance, Results in... March 30, 2023 Nirogacestat May Offer Hope to People with Desmoid Tumors May 1, 2023 Load more HOT NEWS Foodie Fridays: Apple Bok Choy Salad Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL... 6 things you need to know about cervical screening 27-Year-Old Thought She Was Injured Falling Off A Horse, But Then...
